Craig H. Mallinckrodt is Research Fellow in the Decision Sciences and Strategy Group at Eli Lilly and Company. Dr Mallinckrodt has supported drug development in all four clinical phases and in several therapeutic areas. He currently leads Lilly's Advanced Analytics hub for missing data and their Placebo Response Task Force, and is a member of a number of other scientific work groups. He has authored more than 170 papers, book chapters and texts, including extensive works on missing data and longitudinal data analysis in journals such as Statistics in Medicine, Pharmaceutical Statistics, the Journal of Biopharmaceutical Statistics, the Journal of Psychiatric Research, the Archives of General Psychiatry, and Nature. He currently chairs the Drug Information Association's Scientific Working Group on Missing Data.

• Part I. Background and Setting: 1. Why missing data matter; 2. Missing data mechanisms; 3. Estimands; Part II. Preventing Missing Data: 4. Trial design considerations; 5. Trial conduct considerations; Part III. Analytic Considerations: 6. Methods of estimation; 7. Models and modeling considerations; 8. Methods of dealing with missing data; Part IV. Analyses and the Analytic Road Map: 9. Analyses of incomplete data; 10. MNAR analyses; 11. Choosing primary estimands and analyses; 12. The analytic road map; 13. Analyzing incomplete categorical data; 14. Example; 15. Putting principles into practice.

'… this monograph is good value, and I recommend all those involved in the design, conduct or analysis of trials to peruse a copy. Non-statisticians will inevitably be frustrated at times, but if this monograph fosters improved discussion and understanding of the issues raised by missing data in study teams - and how they might be addressed - it will have done its work. In his choice of audience Mallinckrodt set himself a high bar … it has … been cleared. In addition, [his] wry turn of phrase was an unexpected pleasure. You'll miss this if you don't buy it!' James R. Carpenter, Journal of Biopharmaceutical Statistics

Craig H. Mallinckrodt is Research Fellow in the Decision Sciences and Strategy Group at Eli Lilly and Company. Dr Mallinckrodt has supported drug development in all four clinical phases and in several therapeutic areas. He currently leads Lilly's Advanced Analytics hub for missing data and their Placebo Response Task Force, and is a member of a number of other scientific work groups. He has authored more than 170 papers, book chapters and texts, including extensive works on missing data and longitudinal data analysis in journals such as Statistics in Medicine, Pharmaceutical Statistics, the Journal of Biopharmaceutical Statistics, the Journal of Psychiatric Research, the Archives of General Psychiatry, and Nature. He currently chairs the Drug Information Association's Scientific Working Group on Missing Data.

• Part I. Background and Setting: 1. Why missing data matter; 2. Missing data mechanisms; 3. Estimands; Part II. Preventing Missing Data: 4. Trial design considerations; 5. Trial conduct considerations; Part III. Analytic Considerations: 6. Methods of estimation; 7. Models and modeling considerations; 8. Methods of dealing with missing data; Part IV. Analyses and the Analytic Road Map: 9. Analyses of incomplete data; 10. MNAR analyses; 11. Choosing primary estimands and analyses; 12. The analytic road map; 13. Analyzing incomplete categorical data; 14. Example; 15. Putting principles into practice.

'… this monograph is good value, and I recommend all those involved in the design, conduct or analysis of trials to peruse a copy. Non-statisticians will inevitably be frustrated at times, but if this monograph fosters improved discussion and understanding of the issues raised by missing data in study teams - and how they might be addressed - it will have done its work. In his choice of audience Mallinckrodt set himself a high bar … it has … been cleared. In addition, [his] wry turn of phrase was an unexpected pleasure. You'll miss this if you don't buy it!' James R. Carpenter, Journal of Biopharmaceutical Statistics

Craig H. Mallinckrodt is Research Fellow in the Decision Sciences and Strategy Group at Eli Lilly and Company. Dr Mallinckrodt has supported drug development in all four clinical phases and in several therapeutic areas. He currently leads Lilly's Advanced Analytics hub for missing data and their Placebo Response Task Force, and is a member of a number of other scientific work groups. He has authored more than 170 papers, book chapters and texts, including extensive works on missing data and longitudinal data analysis in journals such as Statistics in Medicine, Pharmaceutical Statistics, the Journal of Biopharmaceutical Statistics, the Journal of Psychiatric Research, the Archives of General Psychiatry, and Nature. He currently chairs the Drug Information Association's Scientific Working Group on Missing Data.

• Part I. Background and Setting: 1. Why missing data matter; 2. Missing data mechanisms; 3. Estimands; Part II. Preventing Missing Data: 4. Trial design considerations; 5. Trial conduct considerations; Part III. Analytic Considerations: 6. Methods of estimation; 7. Models and modeling considerations; 8. Methods of dealing with missing data; Part IV. Analyses and the Analytic Road Map: 9. Analyses of incomplete data; 10. MNAR analyses; 11. Choosing primary estimands and analyses; 12. The analytic road map; 13. Analyzing incomplete categorical data; 14. Example; 15. Putting principles into practice.

'… this monograph is good value, and I recommend all those involved in the design, conduct or analysis of trials to peruse a copy. Non-statisticians will inevitably be frustrated at times, but if this monograph fosters improved discussion and understanding of the issues raised by missing data in study teams - and how they might be addressed - it will have done its work. In his choice of audience Mallinckrodt set himself a high bar … it has … been cleared. In addition, [his] wry turn of phrase was an unexpected pleasure. You'll miss this if you don't buy it!' James R. Carpenter, Journal of Biopharmaceutical Statistics